Epigenetics, DNA Methylation and Chromatin Modifying Drugs

被引:255
作者
Szyf, Moshe [1 ]
机构
[1] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada
关键词
DNA methylation; chromatin structure; histone deacetylase inhibitors; methyltransferase; demethylase; epigenetics; HISTONE DEACETYLASE INHIBITOR; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CANCER-CELL-LINES; SMALL-MOLECULE INHIBITOR; ADENOSYL-L-METHIONINE; GENE-EXPRESSION; T-CELLS; CPG METHYLATION; TRICHOSTATIN-A; SILENCED GENES;
D O I
10.1146/annurev-pharmtox-061008-103102
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Evidence is emerging that several diseases and behavioral pathologies result from defects in gene function. The best-studied example is cancer, but other diseases such as autoimmune disease, asthma, type 2 diabetes, metabolic disorders, and autism display aberrant gene expression. Gene function may be altered by either a change in the sequence of the DNA or a change in epigenetic programming of a gene in the absence of a sequence change. With epigenetic drugs, it is possible to reverse aberrant gene expression profiles associated with different disease states. Several epigenetic drugs targeting DNA methylation and historic deacetylation enzymes have been tested in clinical trials. Understanding the epigenetic machinery and the differential roles of its components in specific disease states is essential for developing targeted epigenetic therapy.
引用
收藏
页码:243 / 263
页数:21
相关论文
共 161 条
[11]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[12]  
Bowden Charles L, 2007, Expert Rev Neurother, V7, P9, DOI 10.1586/14737175.7.1.9
[13]   Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases [J].
Brueckner, B ;
Boy, RG ;
Siedlecki, P ;
Musch, T ;
Kliem, HC ;
Zielenkiewicz, P ;
Suhai, S ;
Wiessler, M ;
Lyko, F .
CANCER RESEARCH, 2005, 65 (14) :6305-6311
[14]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[15]   Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo [J].
Campbell, PM ;
Bovenzi, V ;
Szyf, M .
CARCINOGENESIS, 2004, 25 (04) :499-507
[16]   Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1 [J].
Castellano, Sabrina ;
Kuck, Dirk ;
Sala, Marina ;
Novellino, Ettore ;
Lyko, Frank ;
Sbardella, Gianluca .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (07) :2321-2325
[17]   Demethylase activity is directed by histone acetylation [J].
Cervoni, N ;
Szyf, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (44) :40778-40787
[18]   DNA hypomethylation leads to elevated mutation rates [J].
Chen, RZ ;
Pettersson, U ;
Beard, C ;
Jackson-Grusby, L ;
Jaenisch, R .
NATURE, 1998, 395 (6697) :89-93
[19]   Inhibition of DNA methylation and reactivation of silenced genes by zebularine [J].
Cheng, JC ;
Matsen, CB ;
Gonzales, FA ;
Ye, W ;
Greer, S ;
Marquez, VE ;
Jones, PA ;
Selker, EU .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :399-409
[20]   Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells [J].
Chiba, T ;
Yokosuka, O ;
Arai, M ;
Tada, M ;
Fukai, K ;
Imazeki, F ;
Kato, M ;
Seki, N ;
Saisho, H .
JOURNAL OF HEPATOLOGY, 2004, 41 (03) :436-445